We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+82.63%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.06B
AUM Growth
+$2.1B
Cap. Flow
+$394M
Cap. Flow %
7.79%
Top 10 Hldgs %
66.41%
Holding
52
New
9
Increased
18
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$88.8M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$62.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$61M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$52.3M
5
IMMU
Immunomedics Inc
IMMU
+$51.2M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$43M
2
SAGE
Sage Therapeutics
SAGE
+$28.7M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$20.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$15.2M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$930M 18.39%
26,250,000
+1,750,000
+7% +$51.2M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$489M 9.68%
4,286,765
+174,065
+4% +$16.9M
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$333M 6.59%
6,000,000
+1,425,000
+31% +$61M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.03B
$284M 5.62%
10,361,039
+1,350,626
+15% +$44.4M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$269M 5.31%
1,675,000
+90,000
+6% +$12.2M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.6B
$259M 5.12%
1,750,000
-37,000
-2% -$5.08M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.9B
$228M 4.51%
1,850,000
-80,000
-4% -$7.95M
ARGX icon
8
argenx
ARGX
$54.8B
$218M 4.32%
970,000
+33,500
+4% +$5.95M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$182M 3.59%
1,880,000
+445,000
+31% +$37.1M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$166M 3.28%
11,000,000
+50,000
+0.5% +$609K
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
$158M 3.13%
758,500
+43,500
+6% +$7.7M
MRSN
12
DELISTED
Mersana Therapeutics
MRSN
$152M 3.01%
+260,000
New +$88.8M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$155M
$133M 2.62%
466,667
– –
CNST
14
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$120M 2.38%
4,000,000
+350,000
+10% +$12.6M
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$111M 2.2%
1,860,000
-140,000
-7% -$7.49M
ADAP
16
DELISTED
Adaptimmune Therapeutics
ADAP
$100M 1.98%
+10,000,000
New +$62.8M
XLRN
17
DELISTED
Acceleron Pharma
XLRN
$99.1M 1.96%
1,040,000
+180,000
+21% +$17.4M
QURE icon
18
uniQure
QURE
$2.76B
$67.6M 1.34%
1,500,000
-150,000
-9% -$8.86M
RLMD icon
19
Relmada Therapeutics
RLMD
$539M
$63.8M 1.26%
1,425,000
+275,000
+24% +$11.6M
ZGNX
20
DELISTED
Zogenix, Inc.
ZGNX
$60.8M 1.2%
2,250,000
-550,000
-20% -$15.2M
ARNA
21
DELISTED
Arena Pharmaceuticals Inc
ARNA
$59.8M 1.18%
+950,000
New +$52.3M
ATNX
22
DELISTED
Athenex, Inc. Common Stock
ATNX
$53M 1.05%
192,500
-51,250
-21% -$10.8M
ALLO icon
23
Allogene Therapeutics
ALLO
$607M
$48.3M 0.96%
1,128,594
– –
CUE icon
24
Cue Biopharma
CUE
$119M
$45.8M 0.91%
62,333
– –
MDGL icon
25
Madrigal Pharmaceuticals
MDGL
$12.4B
$39.6M 0.78%
350,000
+1,000
+0.3% +$98.3K
1
2 3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Avoro Capital Advisors held 52 positions worth $5.06B, up 71% from $2.96B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Avoro Capital Advisors deployed $394M of net new capital in Q2 2020, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was Mersana Therapeutics: 260,000 shares worth $152M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was PTC Therapeutics, an estimated $43M trimmed.

  • Avoro Capital Advisors's largest Q2 2020 buy was Mersana Therapeutics: 260,000 shares worth $152M.
  • Avoro Capital Advisors added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020, an estimated $61M increase.
  • Avoro Capital Advisors's biggest Q2 2020 reduction was PTC Therapeutics, cutting an estimated $43M.
  • Avoro Capital Advisors fully exited Sage Therapeutics in Q2 2020, selling an estimated $28.7M.
  • Avoro Capital Advisors's ten largest holdings make up 66% of its $5.06B portfolio in Q2 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 7 in Q2 2020.
  • Avoro Capital Advisors's portfolio value rose 71% quarter-over-quarter to $5.06B.

Based on Avoro Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.